Donald Engelman
| Donald Max Engelman | |
|---|---|
| Website | medicine |
| Scientific career | |
| Thesis | Solubilization and Aggregatino Properties of Membrane Components from Mycoplasma Laidlawii (1968) |
| Doctoral students | Mark A. Lemmon |
Donald Max Engelman (born 1941) is Higgins Professor of Biochemistry at Yale University. He is a member of the National Academy of Sciences (1997), fellow of the American Academy of Arts and Sciences, a fellow of the National Institutes of Health, and has been a Guggenheim fellow. He is a director of the Stryker Corporation. He is involved in the creation of new cancer drugs and treatments. For example, Engelman is involved in research to use peptides to aid in destroying tumors.
Engelman has served as Director of Biological Sciences at Yale, an advisor to the Brookhaven National Laboratory, and a consultant to the Los Alamos National Laboratory. He also served as Acting Dean of Yale College in 1991.
Engelman is a graduate (and trustee) of Reed College and Yale University.
Engelman directs the Engelman Laboratory at Yale.
Engelman holds six United States patents for his discoveries.
...
Wikipedia